Ozagrel CYP17 Inhibitors

Ozagrel is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.

Synonyms:

ozagrel;

p-(1-imidazolylmethyl)cinnamic acid;

Ozagrelum;

(E)-4-(1-imidazolylmethyl)cinnamic acid;

(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenic acid;

Cataclot (TN);

2-Propenoic acid,3-(4-(1H-imidazol-1-ylmethyl)phenyl)-,(E);

Properties:

Appearance & Physical State: white powder

Density: 1.17 g/cm3

Boiling Point: 468ºC at 760 mmHg

Melting Point: 223 - 224ºC

Flash Point: 236.8ºC

Refractive Index: 1.593

Prostaglandin Receptor Related Products:

E-7046; Ramatroban; Bimatoprost; Prostaglandin E2; Tafluprost; Carboprost; Treprostinil sodium; MRE-269; Travoprost; Misoprostol; Selexipag; Setipiprant

[1]. Nakazawa, M., et al., [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Yakugaku Zasshi, 1994. 114(12): p. 911-33.

[2]. Li, S.B., et al., In vitro effect of ozagrel on mushroom tyrosinase. Protein J, 2009. 28(3-4): p. 182-8.

[3]. Westphal, M., et al., Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury. Anesthesiology, 2005. 102(5): p. 954-61.